GleamWall
中文EN

VALN Valneva SE IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1836564 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.0%
TTM net income YoY-840.6%
TTM EPS YoY-750.0%
Revenue 3-yr CAGR-21.5%
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-47.0%
Net margin-66.0%
FCF margin-32.8%
EBITDA margin—

Returns

ROE-80.2%
ROA-25.6%
ROIC (approx.)-34.5%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets73.4%
Debt / equity1.69x
Current ratio2.38x
Interest coverage-1.96x

Cash quality & payout

Operating cash flow / net income0.46x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue174.66M169.58M
Cost of revenue107.14M98.54M
Gross profit67.52M71.04M
R&D expense85.30M74.14M
SG&A expense37.32M42.75M
Operating income-82.06M13.33M
Interest expense41.90M23.98M
Pretax income-114.12M-11.49M
Income tax1.07M761,000
Net income-115.19M-12.25M
EBITDA-60.31M32.92M
EPS (basic)-0.68-0.08
EPS (diluted)-0.68-0.08
Weighted avg. shares (diluted)168.18M145.71M
Balance sheet
Cash & equivalents109.65M168.27M
Receivables27.81M35.20M
Inventory50.23M53.66M
Current assets222.54M299.01M
PP&E, netmay include right-of-use assets (IFRS)119.47M138.88M
Intangibles22.35M25.26M
Total assets398.84M500.03M
Current liabilities93.33M114.58M
Short-term debt17.91M20.85M
Long-term debt161.26M166.52M
Total debt179.17M187.37M
Total liabilities292.67M318.78M
Shareholders' equity106.17M181.25M
Net debt69.52M19.10M
Shares outstanding173.42M162.40M
Cash flow statement
Operating cash flow-52.89M-67.22M
Capital expenditure4.42M13.87M
Free cash flow-57.31M-81.08M
Investing cash flow-1.71M76.92M
Financing cash flow-621,00030.68M
Depreciation & amortization21.75M19.59M
Stock-based compensation9.53M7.97M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.